Search
vosoritide (Voxzogo)
Indications:
- treatment of achondroplasia in children >= 2 years whose epiphyses are not yet closed
Dosage:
- 15 ug/ug/day SC
Adverse effects:
- injection site reactions (edema, eythema, itching or pain)
- vomiting
- hypotension
Mechanism of action:
- analog of C-type natriuretic peptide
Related
achondroplasia
General
metabolic agent (metabolic modifier)
Database Correlations
PUBCHEM cid=119058036
References
- FDA News Release. Nov 19, 2021
FDA Approves First Drug to Improve Growth in Children with Most Common Form
of Dwarfism.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism
- Wikipedia: Vosoritide
https://en.wikipedia.org/wiki/Vosoritide
- Savarirayan R, Tofts L, Irving M et al.
Safe and persistent growth-promoting effects of vosoritide in children
with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Genet Med 2021. 23:2443-2447
PMID: 34341520 PMCID: PMC8327889 Free PMC article
- Duggan S
Vosoritide: First Approval
Drugs. 2021 Nov;81(17):2057-2062
PMID: 34694597
- Savarirayan R, Tofts L, Irving M et al
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia:
a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Lancet. 2021. Sept 5, Volume 396, ISSUE 10252, P684-692
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31541-5/fulltext
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Voxzogo (vosoritide) for injection, for subcutaneous use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf